HUTCHMED (HCM) News Today → 41 banks launch ‘crypto dollar’ (From Stansberry Research) (Ad) Free HCM Stock Alerts $20.17 -0.79 (-3.77%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 10:00 AM | globenewswire.comHUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committeesMay 16, 2024 | globenewswire.comHUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 CongressMay 16, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Down to $21.55HUTCHMED (NASDAQ:HCM) Shares Gap Down to $21.55May 16, 2024 | marketbeat.comM&G Investment Management Ltd. Sells 6,896,165 Shares of HUTCHMED (China) Limited (NASDAQ:HCM)M&G Investment Management Ltd. decreased its holdings in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 97.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 188,669 shares of the company'May 15, 2024 | americanbankingnews.comStockNews.com Downgrades HUTCHMED (NASDAQ:HCM) to HoldMay 14, 2024 | stocknews.com3 China Stocks to Watch in MayMay 13, 2024 | globenewswire.comHUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in ChinaMay 13, 2024 | globenewswire.comHUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with HengruiMay 9, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Stock Price Up 6.5%HUTCHMED (NASDAQ:HCM) Trading Up 6.5%May 9, 2024 | stocknews.com3 China Stocks to Accelerate Your Portfolio GainsMay 8, 2024 | globenewswire.comHUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board CommitteeMay 6, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Up to $19.15HUTCHMED (NASDAQ:HCM) Shares Gap Up to $19.15April 29, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Up to $18.16HUTCHMED (NASDAQ:HCM) Shares Gap Up to $18.16April 26, 2024 | globenewswire.comHUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by TakedaApril 17, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Sees Unusually-High Trading VolumeHUTCHMED (NASDAQ:HCM) Sees Unusually-High Trading VolumeApril 16, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Down to $17.66HUTCHMED (NASDAQ:HCM) Shares Gap Down to $17.66April 5, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Stock Price Down 4%HUTCHMED (NASDAQ:HCM) Stock Price Down 4%April 5, 2024 | finance.yahoo.comHUTCHMED Highlights Data to be Presented at AACR Congress 2024April 5, 2024 | marketbeat.comHUTCHMED (China) Limited (NASDAQ:HCM) Forecasted to Post FY2025 Earnings of $0.05 Per ShareHUTCHMED (China) Limited (NASDAQ:HCM - Free Report) - Stock analysts at Trinity Delta issued their FY2025 earnings estimates for HUTCHMED in a research report issued on Wednesday, April 3rd. Trinity Delta analyst L. Gregorek forecasts that the company will post earnings per share of $0.05 for theApril 5, 2024 | globenewswire.comHUTCHMED Highlights Data to be Presented at AACR Congress 2024April 2, 2024 | markets.businessinsider.comHUTCHMED (China) And Innovent's Endometrial Cancer Treatment Granted Priority Review By NMPAApril 2, 2024 | globenewswire.comHUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review StatusMarch 28, 2024 | finance.yahoo.comDo Its Financials Have Any Role To Play In Driving HUTCHMED (China) Limited's (LON:HCM) Stock Up Recently?March 27, 2024 | globenewswire.comHUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLCMarch 21, 2024 | globenewswire.comHUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in ChinaMarch 21, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Down to $17.34HUTCHMED (NASDAQ:HCM) Shares Gap Down to $17.34March 20, 2024 | seekingalpha.comHutchmed Is Turning ProfitableMarch 15, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Stock Price Up 5.5%HUTCHMED (NASDAQ:HCM) Trading 5.5% HigherMarch 14, 2024 | msn.comAffimed N.V., Hutchmed, Annexon among healthcare moversMarch 11, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Raised to Buy at StockNews.comStockNews.com upgraded HUTCHMED from a "hold" rating to a "buy" rating in a report on Monday.March 7, 2024 | marketbeat.comHUTCHMED (China) Limited (NASDAQ:HCM) Stake Cut by Schroder Investment Management GroupSchroder Investment Management Group reduced its holdings in HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 8.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,219,168 shares of theMarch 5, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Down to $15.12HUTCHMED (NASDAQ:HCM) Shares Gap Down to $15.12March 1, 2024 | seekingalpha.comHUTCHMED (China) Limited (HCM) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finance.yahoo.comHUTCHMED (China) Full Year 2023 Earnings: EPS: US$0.12 (vs US$0.43 loss in FY 2022)February 28, 2024 | globenewswire.comHUTCHMED Reports 2023 Full Year Results and Provides Business UpdatesFebruary 27, 2024 | marketbeat.comHUTCHMED (HCM) to Release Quarterly Earnings on WednesdayHUTCHMED (NASDAQ:HCM) will be releasing its 12/31/2023 earnings before the market opens on Wednesday, February 28, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=395260)February 25, 2024 | marketbeat.comAcadian Asset Management LLC Makes New Investment in HUTCHMED (China) Limited (NASDAQ:HCM)Acadian Asset Management LLC acquired a new position in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 193,811 shares of the company's stockFebruary 17, 2024 | finance.yahoo.comHCM Mar 2024 17.500 callFebruary 14, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Down to $14.01HUTCHMED (NASDAQ:HCM) Shares Gap Down to $14.01February 6, 2024 | finance.yahoo.comHUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series SessionFebruary 6, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Up to $12.08HUTCHMED (NASDAQ:HCM) Shares Gap Up to $12.08February 2, 2024 | finanznachrichten.deHUTCHMED (China) Limited: HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic PartnershipFebruary 2, 2024 | finance.yahoo.comInmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMEDJanuary 30, 2024 | finance.yahoo.comHUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal CancerJanuary 29, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Sees Strong Trading VolumeHUTCHMED (NASDAQ:HCM) Sees Unusually-High Trading VolumeJanuary 17, 2024 | marketbeat.comHUTCHMED (China) Limited (NASDAQ:HCM) Sees Large Decrease in Short InterestHUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) was the target of a significant drop in short interest in December. As of December 31st, there was short interest totalling 542,100 shares, a drop of 12.6% from the December 15th total of 620,400 shares. Based on an average daily volume of 140,700 shares, the short-interest ratio is presently 3.9 days.January 11, 2024 | msn.comChinese regulators accept HUTCHMED application for solveplenibJanuary 10, 2024 | finance.yahoo.comHUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review StatusJanuary 3, 2024 | marketbeat.comHUTCHMED (China) Limited (NASDAQ:HCM) Short Interest UpdateHUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 620,400 shares, a growth of 12.9% from the November 30th total of 549,600 shares. Based on an average daily trading volume, of 143,200 shares, the short-interest ratio is presently 4.3 days.December 24, 2023 | ca.finance.yahoo.comHUTCHMED (China) Limited (0013.HK) Get HUTCHMED News Delivered to You Automatically Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter. Email Address The Overlooked Retirement Asset You Probably Don’t Own (Ad)4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm. Click here to access the Crypto Retirement Blueprint now. HCM Media Mentions By Week HCM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HCM News Sentiment▼0.580.42▲Average Medical News Sentiment HCM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HCM Articles This Week▼81▲HCM Articles Average Week Get HUTCHMED News Delivered to You Automatically Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: INSM News AXSM News CRNX News PBH News RARE News PRGO News ALKS News BHVN News SMMT News IDYA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HCM) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyUrgent Nvidia WarningAltimetryElon’s New Device is About to Shock the WorldInvestorPlace"The Biggest Drug Ever" Is ComingBehind the MarketsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist My Default Watchlist Adding HUTCHMED (China) Limited You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
